Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies.

J Immunother Cancer · 2026 · PMC12878408 · PMID 41638870

Europe PMC DOI

hedged sentences

0.0990

closest p · 2.0× alpha

0.2200

boldest claim

The sentences

a trend towards significancep=0.099so close (0.05 < p ≤ 0.1)

It is worth noting that the distribution of single-station versus multistation N2 disease showed a trend towards significance (p=0.099), with Group A having a higher proportion of single-station N2 disease (90%) compared with Group C (72%) however the extent of clinical N2 disease (single vs multi) did not correlate with survival in any of the groups.

also in 2,760 other papers

did not reach statistical significancep=0.22not close (p > 0.1)

However, at the final OS analysis, the OS benefit did not reach statistical significance (median OS 23.1 vs 16.9 months; HR 0.87, p=0.22), and the primary OS endpoint was not met.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.